ライフサイエンスコーパス: fibrosarcoma

1 new case of a very rare entity, a presacral fibrosarcoma.

2 and the immunogenic, chemically induced LiHa fibrosarcoma.

3 on in certain types of human cells including fibrosarcoma.

4 as, 4 malignant fibrous histiocytomas, and 1 fibrosarcoma.

5 be susceptible to non-mammary tumors such as fibrosarcoma.

6 l to show that aged mice develop MSC-derived fibrosarcomas.

7 tion, and generated Vhl(-)(/)(-) MEF-derived fibrosarcomas.

8 proliferation rates of Vhl(-)(/)(-) MEFs and fibrosarcomas.

9 ocal control for retroperitoneal sarcomas or fibrosarcomas.

10 by cisplatin treatment of radiation-induced fibrosarcoma 1 (RIF-1) tumor-bearing mice.

11 ost common histologic diagnosis, followed by fibrosarcoma (15%) and angiosarcoma (15%).

12 easure fluctuations in vascular pO(2) in rat fibrosarcomas, 9L gliomas, and R3230 mammary adenocarcin

13 e in many cell types, including HT1080 human fibrosarcoma and B16F10 mouse melanoma cells.

14 Congenital (infantile) fibrosarcoma and cellular mesoblastic nephroma have been

15 In WEHI 164 fibrosarcoma and EL4 and A20/2J lymphoma models, PT-100

16 We retrieved an in vivo growing MCA205 fibrosarcoma and isolated tumor cell clones that produce

17 For example, both the HT-1080 fibrosarcoma and MAT-LyLu cell lines fail to assemble a

18 cient tumor variants arise in both cutaneous fibrosarcoma and melanoma as a result of immune stress i

19 In fibrosarcoma and neuroblastoma cells, huntingtin shows d

20 ed by highly disseminating variants of human fibrosarcoma and prostate carcinoma recruit elevated lev

21 ce-free survival rate for other-than-primary fibrosarcoma and retroperitoneal sarcomas, and independe

22 ighly invasive cell lines, the human HT-1080 fibrosarcoma and the human MDA-MB-231 adenocarcinoma, we

23 We show that the endothelium in MCA/129 fibrosarcomas and B16 melanomas exhibits a wild-type apo

24 vious studies provided evidence that MCA/129 fibrosarcomas and B16 melanomas grow 2- to 4-fold faster

25 ata provide definitive evidence that MCA/129 fibrosarcomas and B16F1 melanomas do not elicit a host i

26 MCA/129 fibrosarcomas and B16F1 melanomas grown in apoptosis-res

27 ic hyperplasia of VEGF-C-overexpressing T241 fibrosarcomas and decreases the delivery of metastatic t

28 cell lines in vitro, including MCA205 murine fibrosarcomas and human head and neck tumors.

29 ig in T cell-mediated responses to cutaneous fibrosarcomas and suggest the loss of Mig expression as

30 Frzb transfection of HT1080 (fibrosarcoma) and SW872 (liposarcoma) cell lines and the

31 mary adenocarcinoma, 5.5% +/- 0.8 for HT1080 fibrosarcoma, and 6.6% +/- 0.9 for EOMA hemangioendothel

32 cancer cell types, including breast cancer, fibrosarcoma, and cervical cancer cells, with minimal ef

33 5 human mammary adenocarcinoma, HT1080 human fibrosarcoma, and EOMA hemangioendothelioma--were implan

34 r-specific T cell responses against the CMS5 fibrosarcoma, and found a deficit in the efficacy of nai

35 ncer cell types, including breast carcinoma, fibrosarcoma, and melanoma.

36 used MDA-MB-231 breast carcinoma and HT1080 fibrosarcoma as cell models.

37 to characterize Ang-4 actions on T241 murine fibrosarcoma-associated vessels in mice.

38 ssion in Drosophila The knockdown of 5MP1 in fibrosarcoma attenuates ATF4 expression and its tumor fo

39 CTL, and Ts cells from the OFA/iLRP+ MCA1315 fibrosarcoma-bearing BALB/c mice or from BALB/c mice vac

40 oped in naive mice or mice cured of UV-2237M fibrosarcomas but not in mice cured of K-1735M2 melanoma

41 Treatment of an established MCA205 mouse fibrosarcoma by single intratumoral injection of AdIL-1H

42 otif) receptor 5 (CXCR5), musculoaponeurotic fibrosarcoma (c-Maf), Bcl6, basic leucine zipper transcr

43 actor 2 (Nrf2) to c-avian musculoaponeurotic fibrosarcoma (c-Maf)/V-maf musculoaponeurotic fibrosarco

44 underlie the mechanical hyperalgesia in the fibrosarcoma cancer model.

45 c ability of conditioned media obtained from fibrosarcoma, carcinoma, and osteosarcoma cells and thei

46 induction of these proapoptotic signals in a fibrosarcoma cell line (2ftgh) and a Stat1-deficient clo

47 s (SNU387, SNU449, SNU398, and PLC/PRF/5), a fibrosarcoma cell line (HT1080), and colorectal carcinom

48 3 suppresses the tumorigenicity of the mouse fibrosarcoma cell line A9.

49 to quantify methionine metabolism in a human fibrosarcoma cell line and study how methionine salvage

50 ime resolved live-cell imaging and HT1080, a fibrosarcoma cell line commonly used to study cell migra

51 uman lung and skin fibroblasts and the human fibrosarcoma cell line HT-1080.

52 d by intracellular protein kinase B (PKB) in fibrosarcoma cell line HT1080 and in NIH-3T3 cells.

53 a at membrane ruffles in the highly invasive fibrosarcoma cell line HT1080.

54 3-specific ribozyme, expressed it in a human fibrosarcoma cell line in which Sp1 protein and Sp3 prot

55 bly transfected the highly tumorigenic mouse fibrosarcoma cell line MCA-205 with Ad5-E1A or a mutant

56 n of an oncogene, and into a patient-derived fibrosarcoma cell line.

57 We examined VEGFxxxb expression in mouse fibrosarcoma cell lines expressing all or individual VEG

58 Here we investigate four adult male HT-1080 fibrosarcoma cell lines expressing ectopic human XIST an

59 Thus, these two fibrosarcoma cell lines provided endogenous negative con

60 els of Sp1 were found in the patient-derived fibrosarcoma cell lines tested, and in the tumors formed

61 Mouse fibrosarcoma cell lines that are capable of expressing a

62 ctor Sp1 in the formation of tumors by human fibrosarcoma cell lines that overexpress it, we found th

63 ls of these two transcription factors in the fibrosarcoma cell lines were reduced to near that found

64 e of wild-type and a variety of mutant human fibrosarcoma cell lines, including mutant U5A cells, whi

65 show that in breast, prostate, melanoma, and fibrosarcoma cell lines, the level of active phospho-ERK

66 was down-regulated in human patient-derived fibrosarcoma cell lines.

67 In contrast, FN fragments increased HT1080 fibrosarcoma cell migration over intact FN.

68 olated from murine L3-L6 DRGs ipsilateral to fibrosarcoma cell tumors.

69 Macrophage viability and activity and fibrosarcoma cell viability were statistically analyzed

70 In wild-type fibrosarcoma cells (2fTGH), IFN activates STAT1, STAT2,

71 Genetic mapping studies using human fibrosarcoma cells (H4) that stably expressed mutant for

72 Human fibrosarcoma cells (HT-1080) and murine macrophages were

73 HCV(1-2962) genomic clone (HCV-FL) in human fibrosarcoma cells (HT1080) inhibited gamma interferon (

74 Human fibrosarcoma cells (HT1080) lacking mitochondrial DNA (r

75 in the time-dependent cytotoxic response of fibrosarcoma cells (HT1080) to free OX and OX-loaded lip

76 ost effective in fusing MMP-expressing human fibrosarcoma cells (HT1080).

77 E2) within the hTERT core promoter in HT1080 fibrosarcoma cells and HCT116 colon cancer cells and NME

78 ependent and -independent growth of A9 mouse fibrosarcoma cells and inhibited tumor formation in nude

79 lated by dexamethasone stimulation of HT1080 fibrosarcoma cells and is required for fibronectin (FN)

80 ollagen-induced MT1-MMP activation in HT1080 fibrosarcoma cells and MT1-MMP function in MDA-MB231 bre

81 l (TC-EC) signaling, we used highly invasive fibrosarcoma cells and quantified tumor cell migration d

82 P-9 expression in transformed leukocytes and fibrosarcoma cells and that proinflammatory phorbol este

83 but unexpectedly also in VEGF188 and VEGF164 fibrosarcoma cells and tumours, where splicing to produc

84 ured with fibrosarcoma cells indicating that fibrosarcoma cells are sufficient to evoke phenotypic ch

85 Furthermore, using HT-1080 fibrosarcoma cells as a model system, we have investigat

86 In 3D matrices, fibrosarcoma cells as well as migrating breast, pancreat

87 rapidly replicated and killed HT-1080 human fibrosarcoma cells but spread poorly in CCD-1122Sk human

88 augmented the tumorigenicity of human HT1080 fibrosarcoma cells by increasing their DNA synthesis, mi

89 that ectopic p21 expression in human HT1080 fibrosarcoma cells causes not only dephosphorylation but

90 purified growth factors or by human HT-1080 fibrosarcoma cells correlated with the initial influx of

91 ransfection of siRNA-resistant constructs in fibrosarcoma cells demonstrated that impairment of the e

92 Ectopic expression of Noxa in HT1080 fibrosarcoma cells enhanced cellular sensitivity to vira

93 We show that STAT1-deficient human fibrosarcoma cells exhibited enhanced autophagic flux as

94 ilar selective defects are observed in human fibrosarcoma cells expressing a mutant JAK1.

95 tasis in vivo, we stably transfected HT-1080 fibrosarcoma cells expressing either fully active wild-t

96 Syngeneic mice challenged with LiHa fibrosarcoma cells expressing Tyrp1-WM, but not native T

97 hibited potent antitumor activity in HT-1080 fibrosarcoma cells grafted onto chick chorioallantoic me

98 vessel density in tumors produced by MCA102 fibrosarcoma cells implanted s.c. into syngeneic mice.

99 C3H mice were injected with osteolytic fibrosarcoma cells in and around the calcaneus bone.

100 tterns of collagen I matrix deformation near fibrosarcoma cells in the absence and presence of inhibi

101 ort hairpin RNA knockdown of Gp78 in HT-1080 fibrosarcoma cells increased mitofusin levels and reduce

102 s with the plasma membrane of HeLa cells and fibrosarcoma cells independently of F-actin.

103 creased in small DRG neurons cocultured with fibrosarcoma cells indicating that fibrosarcoma cells ar

104 Virus from HT-1080 fibrosarcoma cells infected with the human retrovirus XM

105 T cells also eradicated CEA(+) fibrosarcoma cells injected 45 days later.

106 Unilateral injection of osteolytic fibrosarcoma cells into and around the calcaneus bone re

107 orsal horn neurons following implantation of fibrosarcoma cells into and around the calcaneus bone, a

108 tumors formed after injection of osteolytic fibrosarcoma cells into the calcaneus bone of mice, cuta

109 nant K5-induced apoptosis of stressed HT1080 fibrosarcoma cells involves enhanced activity of caspase

110 sing EG7 lymphoma cells and CMS5 MCA-induced fibrosarcoma cells naturally expressing mutated extracel

111 ependent of p53 up-regulation, human HT-1080 fibrosarcoma cells null for p14(ARF) and harboring a def

112 ILP formation in malignant cancer cells and fibrosarcoma cells occurs across a much wider range of E

113 ntified the migration patterns of individual fibrosarcoma cells on 2D substrates and in 3D collagen m

114 ion of MCF-7 breast cancer cells and HT-1080 fibrosarcoma cells on serum-coated surfaces is stimulate

115 yo model involving grafting of human HT-1080 fibrosarcoma cells on the chorioallantoic membrane was u

116 On day 7, UV-2237M fibrosarcoma cells or K-1735M2 cells were implanted into

117 Six weeks later, UV-2237M fibrosarcoma cells or K-1735M2 melanoma cells were injec

118 ported that IFN-beta induction of beta-R1 in fibrosarcoma cells required transcription factors ISGF-3

119 mbinant 44-MT1 (Gly(285)-Val(582)) in HT1080 fibrosarcoma cells results in enhanced pro-MMP-2 activat

120 Overexpression of Sod2 in HT-1080 fibrosarcoma cells significantly enhanced their migratio

121 produced at a high titer from human HT-1080 fibrosarcoma cells that express TRIM5alpha (Ref1), showi

122 lagen on proliferation of human melanoma and fibrosarcoma cells that involves activation of the tyros

123 ng of BRAF(V599E) or wild-type BRAF in human fibrosarcoma cells that lack the BRAF(V599E) mutation do

124 ed fluorescent protein-labeled HT-1080 human fibrosarcoma cells to determine clonality by simple fluo

125 a(V)beta(3) inhibited the adhesion of HT1080 fibrosarcoma cells to gB(RGD), while antibodies to alpha

126 human microvascular endothelial and HT-1080 fibrosarcoma cells to immobilized thrombospondin-1 and r

127 mimicked by coculturing DRG neurons with the fibrosarcoma cells used to generate the tumors.

128 udy identifies that MET in HT1080 human lung fibrosarcoma cells was initiated by down-regulation of t

129 ) on tumour cell behaviour, using a panel of fibrosarcoma cells we developed that express them indivi

130 ccurred when DRG neurons from naive mice and fibrosarcoma cells were cocultured for 48 h.

131 Fibrosarcoma cells were incubated with (18)F-FDG and exp

132 QRsP-11 fibrosarcoma cells were injected into the spleens of syn

133 Labeled fibrosarcoma cells were injected subcutaneously into thr

134 ATF4-deficient human fibrosarcoma cells were unable to colonize the lungs in

135 Pretreatment of HT1080-derived fibrosarcoma cells with pharmacological inhibitors of PI

136 iety of tumor cell lines, including HT-1080 (fibrosarcoma cells); HeLa (cervical carcinoma cells); A5

137 ty for mouse embryonic fibroblasts and human fibrosarcoma cells, across a wide range of matrix compli

138 protein kinase kinase 1 activities in HT1080 fibrosarcoma cells, and epidermal growth factor-induced

139 ed by human monocytic U937 cells and HT-1080 fibrosarcoma cells, did not stimulate angiogenesis.

140 ates transport of ARSG to lysosomes in human fibrosarcoma cells, due to impaired mannose 6-phosphate

141 HT1080 human fibrosarcoma cells, labeled in the nucleus with green fl

142 5F5/M10 mammary epithelial cell line, HT1080 fibrosarcoma cells, primary mouse embryonic fibroblasts,

143 In HT1080 fibrosarcoma cells, small interfering RNA-directed knock

144 asal levels in p53-null human fibroblasts or fibrosarcoma cells, the T18A mutant accumulated 5-10-fol

145 pplying our system to lamin-A overexpressing fibrosarcoma cells, we found a markedly reduced stretch

146 iated adhesion and migration of HT1080 human fibrosarcoma cells, which lack any GPIb, on collagen.

147 oma, U937 pro-monocytic leukemia, and HT1080 fibrosarcoma cells, XAF1 mRNA was strongly up-regulated

148 ic spindle apparatus in variant HT1080 human fibrosarcoma cells.

149 n neutrophil-like HL-60 cells, or in HT-1080 fibrosarcoma cells.

150 the proliferation of human breast cancer and fibrosarcoma cells.

151 e migration of DU-145 cells and also HT-1080 fibrosarcoma cells.

152 man MB435S breast cancer cells, and human H4 fibrosarcoma cells.

153 aB activation in JAK1-deficient mutant human fibrosarcoma cells.

154 surface molecules expressed by HT-1080 human fibrosarcoma cells.

155 n plasmids and transfected into HT1080 human fibrosarcoma cells.

156 F-kappaB activation in TYK2-deficient mutant fibrosarcoma cells.

157 terize the Ca(2+) signaling events in HT1080 fibrosarcoma cells.

158 udies, mice were injected s.c. with UV-2237M fibrosarcoma cells.

159 ogous recombination in cultured HT-1080 male fibrosarcoma cells.

160 confirmed in studies of E1A-expressing human fibrosarcoma cells.

161 nt only in fibroblasts and HT1080 human skin fibrosarcoma cells.

162 for the enzyme naturally expressed in HT1080 fibrosarcoma cells.

163 ind after shear-induced detachment of HT1080 fibrosarcoma cells.

164 S and the results of STAT1 deletion in human fibrosarcoma cells.

165 oculated with either human bladder cancer or fibrosarcoma cells.

166 ansient in small DRG neurons cocultured with fibrosarcoma cells.

167 oblasts, the nuclear piston is not active in fibrosarcoma cells.

168 earing mice as well as those cocultured with fibrosarcoma cells.

169 or RalBP1 enhanced migration and invasion of fibrosarcoma cells.

170 eness against a transplanted tERK-expressing fibrosarcoma challenge, was lost within days of transfer

171 After the injection of a GR9-B11 mouse fibrosarcoma clone into syngeneic BALB/c mice, all anima

172 PORCN genomic locus, establishing two HT1080 fibrosarcoma clones null for PORCN activity that facilit

173 bserved in the hESc lines, compared with the fibrosarcoma-derived control cells, where the exogenous

174 y inhibited the growth of both p53-deficient fibrosarcomas expressing H-rasG12V and acute myeloid leu

175 Fibrosarcomas expressing only VEGF188 (fs188) or wild ty

176 FA therapy to mice bearing luminescent mouse fibrosarcomas expressing single VEGFA isoforms or their

177 We generated VEGF-null fibrosarcomas from VEGF-loxP mouse embryonic fibroblasts

178 ial pressure of oxygen (pO2) fluctuations in fibrosarcoma (FSA) and 9L tumors under air and O2 breath

179 R3230 mammary adenocarcinomas (R3230Ac), fibrosarcomas (FSA), and 9L gliomas (9L) were used in th

180 locally advanced methylcholanthrene-induced fibrosarcoma grown in BALB/c mice.

181 D47 blockade with irradiation did not affect fibrosarcoma growth in T cell-deficient mice, whereas ad

182 imply an unusual feature of LLC tumors--T241 fibrosarcoma growth in the footpad was also restricted b

183 recent studies in methylcholanthrene-induced fibrosarcomas have indicated the appearance and rapid gr

184 avasating (HT-lo/diss) variants of the human fibrosarcoma HT-1080 cell line to determine which enzyme

185 d by employing two variants of human HT-1080 fibrosarcoma, HT-hi/diss and HT-lo/diss, which differ by

186 ion of homotypic cell-cell adhesion in human fibrosarcoma HT1080 and mouse NIH3T3 cells.

187 find that stable expression of LRP6 in human fibrosarcoma HT1080 cells alters subcellular beta-cateni

188 n the PTK7 function, we used highly invasive fibrosarcoma HT1080 cells as a model system.

189 nase-inactive mutants of hMINK beta in human fibrosarcoma HT1080 cells enhanced cell spreading, actin

190 ed that DNA ligase III was degraded in human fibrosarcoma HT1080 cells following exposure to gamma-ra

191 l-matrix adhesion-mediated phenotypes, human fibrosarcoma HT1080 cells were transfected with retrovir

192 etwork in neutrophil-like HL-60 cells, human fibrosarcoma HT1080 cells, and mouse NIH 3T3 fibroblast

193 Mesenchymal human fibrosarcoma HT1080 cells, which have naturally high lev

194 ith a FLAG tag in breast carcinoma MCF-7 and fibrosarcoma HT1080 cells.

195 adder RT112 and colorectal HT29, moderate in fibrosarcoma HT1080 to negligible (i.e. spontaneous kf =

196 nguished the secretion of PGI/AMF in a human fibrosarcoma HT1080, whereas the control siRNA showed no

197 human lung adenocarcinoma (A549), and human fibrosarcoma (HT1080) cells and access their potential a

198 edema model and 81% inhibition in the human fibrosarcoma (HT1080) tumor growth model when given oral

199 ld); breast tumors, MDA-MB-468 (2-fold); and fibrosarcoma, HT1080 (3-fold); and in p53-null murine em

200 against Lewis lung carcinoma (LLC) and T241 (fibrosarcoma) implanted at a distant site.

201 ibited the growth of B16 melanoma and MCA205 fibrosarcoma in a dose-dependent manner without signific

202 Tomography (CT) features of a rare presacral fibrosarcoma in an adult woman, in whom the diagnosis wa

203 type in vitro, and promotes the formation of fibrosarcoma in nude mice.

204 These cell lines form fibrosarcomas in athymic mice with a very short latency,

205 Compared with wild-type mice, fibrosarcomas in hrg(-/-) mice were more hypoxic, necrot

206 Cells from dense foci produced malignant fibrosarcomas in mice, thereby exhibiting a positive rel

207 oblasts in vitro and in inducing MEF-derived fibrosarcomas in vivo in nude mice.

208 nstruction of VEGF164 and VEGF188 expressing fibrosarcomas, in which exon 7 is fused to the conventio

209 have no spontaneous tumors and show similar fibrosarcoma incidence after MCA inoculation compared to

210 ll lines B16 (melanoma), MCA207, and MCA102 (fibrosarcoma) increased C16 and C24 ceramide as determin

211 In vivo studies showed that fibrosarcomas induced by the carcinogen benzo[alpha]pyre

212 that overexpression of VEGF-A in murine T241 fibrosarcomas induced the growth of peritumoral lymphati

213 In a murine fibrosarcoma L(d)-expressing Ag104, these cells made up

214 oma, one with synovial sarcoma, and one with fibrosarcoma) lasting 4 months or longer.

215 The s.c. methylcholanthrene-induced fibrosarcoma leg tumors were treated with ATO alone (10

216 so developed several malignancies, including fibrosarcoma, leukemia, leiomyosarcoma, and myxosarcoma,

217 Clones derived from human fibrosarcoma line HT1080 cells transduced with an HIV ve

218 rm-expressing transgenic mice from which the fibrosarcoma lines were developed.

219 d had one of the following histopathologies: fibrosarcoma, liposarcoma, leiomyosarcoma, malignant fib

220 owed growth of syngeneic tumors derived from fibrosarcoma, lymphoma, melanoma, and mastocytoma cell l

221 e report that IL-10 and c-musculoaponeurotic fibrosarcoma (Maf) induce their mutual expression in inf

222 ctor of life span in mice dying of lymphoma, fibrosarcoma, mammary adenocarcinoma, or of all other ca

223 w that the intravital visualization of human fibrosarcoma-mediated tumor angiogenesis using fluoresce

224 t soluble VEGFA isoform expression increases fibrosarcoma metastasis through multiple mechanisms that

225 Furthermore, we clearly show with a fibrosarcoma model Ag104L(d) that local treatment can ge

226 in the nonrelated methylcholanthrene-induced fibrosarcoma model.

227 is described and assessed in vivo in a human fibrosarcoma murine xenograft.

228 round cell tumors, and one each of infantile fibrosarcoma, myxoid liposarcoma, cellular congenital me

229 ngiosarcomas (n = 16), 0 Ewing (n = 13), one fibrosarcoma (n = 12), six leiomyosarcomas (n = 29), sev

230 Furthermore, neither MCA/129 fibrosarcoma nor B16 melanoma tumors showed differences

231 etastatic RAD-105 tumor cells derived from a fibrosarcoma of a Stat1 knockout mouse were reconstitute

232 model, recapitulated the naturally occurring fibrosarcomas of the aged mice with gene expression chan

233 omeobox (Pdx)-1 and v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A (MafA), two crit

234 ranscription factor v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (MAFB) in osteoc

235 e of suppression of v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B, which promotes

236 domain of the v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (MAF), a leucine zipper-co

237 event is translocation of musculoaponeurotic fibrosarcoma oncogene homolog (MAF), a transcriptional a

238 regulation of v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog G (MAFG), a transcriptiona

239 ibrosarcoma (c-Maf)/V-maf musculoaponeurotic fibrosarcoma oncogene homolog G (MafG).

240 ns restored c-Fos, c-Jun, musculoaponeurotic fibrosarcoma oncogene homolog K, and PU.1 binding to the

241 transcription factor MAF (musculoaponeurotic fibrosarcoma oncogene homolog).

242 sed by mutations in v-maf musculoaponeurotic fibrosarcoma oncogene ortholog B (MAFB), matrix metallop

243 Most importantly, treatment of fibrosarcoma or breast carcinoma cells with a DNA methyl

244 e were injected s.c. with syngeneic UV-2237M fibrosarcoma or K-1735M2 melanoma cells.

245 Mice with FSa fibrosarcoma or MCa4 carcinoma were subjected to EPR O2

246 , we show that hrg(-/-) mice challenged with fibrosarcoma or pancreatic carcinoma grow larger tumors

247 sensitive sites in normal fibroblasts versus fibrosarcoma or those transfected with oncogenes, nonmal

248 Rapidly accelerated fibrosarcoma (RAF) inhibitors are first-line treatments

249 in conjunction with the rapidly accelerated fibrosarcoma (RAF) kinase inhibitor vemurafenib to treat

250 inase B (PKB or AKT) and rapidly accelerated fibrosarcoma (RAF) proteins regardless of matrix stiffne

251 we show that cPLA2alpha, rapidly accelerated fibrosarcoma (RAF)/MEK/ERK, and PI3K/AKT signaling pathw

252 of the Rat Sarcoma (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen signal-regulated kinase-extra

253 e in melanoma-reactive CD8(+) T cells and in fibrosarcoma-reactive polyclonal T cells enhanced the pe

254 te-responsive element for musculoaponeurotic fibrosarcoma recognition and functions as an enhancer el

255 Mutant forms of the musculo-aponeurotic fibrosarcoma recognition element did not bind NRF2.

256 We identified a musculo-aponeurotic fibrosarcoma recognition element in the promoter of ITPR

257 endothelioma, Sertoli-Leydig cell tumor, and fibrosarcoma, respectively.

258 imers was also compared in radiation-induced fibrosarcoma (RIF) tumor cells at variable drug/light do

259 nalogues was determined in radiation-induced fibrosarcoma (RIF) tumor cells.

260 und to be active in vitro [radiation-induced fibrosarcoma (RIF) tumor cells].

261 COX-2 was also elevated in radiation-induced fibrosarcoma (RIF) tumors after treatment with PDT.

262 ormal and tumor tissues of radiation-induced fibrosarcoma (RIF-1) tumor-bearing mice and to examine t

263 Radiation-induced fibrosarcoma (RIF-1) tumors grown in C(3)H mice were tre

264 on the glycolytic rate of radiation-induced fibrosarcomas (RIF-1) was measured in vivo in C3H mice b

265 HPP-VG76e, two subclones of the HT1080 human fibrosarcoma selected on the basis of differing VEGF pro

266 Histologic assessment of all tumors revealed fibrosarcomas, squamous carcinomas, and mixed tumors.

267 cells exhibited normal cytotoxicity against fibrosarcoma targets, yet had impaired adhesion to and k

268 opment of 3-methylcholanthrene (MCA)-induced fibrosarcomas through a mechanism relying upon IFN-gamma

269 endent angiogenesis, in mBD14-overexpressing fibrosarcoma tumor cells abolished enhanced solid tumor

270 es with lymphotoxin beta-receptor-expressing fibrosarcoma tumor cells has been identified as a new CX

271 Similar results were obtained in the RIF-1 fibrosarcoma tumor model.

272 ted by IL-21 in the B16F1 melanoma and MethA fibrosarcoma tumor models in mice.

273 In PDT studies radiation-induced fibrosarcoma tumor SO(2) was measured immediately before

274 -defensin superfamily, is expressed in mouse fibrosarcoma tumor tissue.

275 ity, and distribution in a radiation-induced fibrosarcoma tumor transplanted into C3H mice.

276 rmined in C3H mice bearing radiation induced fibrosarcoma tumors as a function of variable drug doses

277 ring A) was used to treat radiation-induced fibrosarcoma tumors before X-ray treatment.

278 MT and QT fibrosarcoma tumors grew 2 to 3 times larger than WT tum

279 d glutathione was detected in s.c. implanted fibrosarcoma tumors in anesthetized rats following infus

280 nges in SO(2) and pO(2) of radiation-induced fibrosarcoma tumors measured by reflectance spectroscopy

281 Mice bearing radiation-induced fibrosarcoma tumors were treated with Photofrin-mediated

282 us for MTF-1 (MTF-1-/-) were used to develop fibrosarcoma tumors.

283 s generated a pair of congenic human HT-1080 fibrosarcoma variants (i.e. HT-hi/diss and HT-lo/diss) d

284 PGI/AMF cellular expression in HT1080 human fibrosarcoma was down-regulated by small interfering RNA

285 d a red fluorescent protein-expressing human fibrosarcoma was implanted s.c. in the ND-GFP nude mice.

286 nhanced tumor growth of mBD14-overexpressing fibrosarcomas was abolished in CCR6-deficient mice, whic

287 singly, growth of both Vhl(-)(/)(-) MEFs and fibrosarcomas was impaired, although tumor vascularity w

288 potentiate radiotherapeutic outcome (HT1080 fibrosarcoma), we witnessed complete tumor regression wh

289 In a nude mouse model of human fibrosarcoma, we show that the IFN-sensitive NDV variant

290 d tumors in aged C57BL/6 mice are frequently fibrosarcomas, we used a genetically tagged bone marrow

291 MDA-MB-435-RFP breast cancer, and HT1080-RFP fibrosarcoma were transplanted to the transgenic GFP nud

292 reover, the overall incidence and latency of fibrosarcomas were substantially increased and shortened

293 uploid; Mad1(+/-), but not wt, MEFs produced fibrosarcomas when explanted into nude mice.

294 ntly, MLTK-alpha-overexpressing cells formed fibrosarcomas when injected s.c. into athymic nude mice,

295 various pathological alterations, including fibrosarcomas, when its transgenic expression is restric

296 We treated mice bearing WEHI-164 fibrosarcoma with a combination of F8-TNF and doxorubici

297 antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth

298 ouse uterine edema model and an HT1080 human fibrosarcoma xenograft tumor model.

299 antimitotic cancer drugs over 8 d in HT-1080 fibrosarcoma xenografts in living mice using a data set

300 nd decreases vascular density in preclinical fibrosarcoma xenografts.